TEGSEDI (inotersen) injection, for subcutaneous use. Initial U.S. Approval: 2018

TEGSEDI (inotersen) injection, for subcutaneous use. Initial U.S. Approval: 2018

TEGSEDI is a transthyretin-directed antisense oligonucleotide indicated for treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Injection: 284 mg/ 1.5 mL in a single-dose prefilled syringe.
Manufactured By: Ionis Pharmaceuticals, Inc.
Prescribing Information URL: Click Here

Access to TEGSEDI (inotersen) injection: Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from Medvitaz Pharma Solutions.

Inotersen, sold under the brand name Tegsedi, is a medication used for the treatment of nerve damage in adults with hereditary transthyretin-mediated amyloidosis.The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.


There are no reviews yet.

Add a review

Neeraj Nagpal

Head of Operations

 The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.

Contact Our Team

Contact us and we will reply as soon as possible!

    need help?

     MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.